Oct 04th 2012 - Edison Investment Research today published a report on Morphosys entitled "MOR Prospects Of A Deal". In summary, the report says:
The initial data from the Phase Ib/IIa trial in rheumatoid arthritis (RA) with MOR103 increase the likelihood that MorphoSys can partner the product ahead of the Phase Ib trial in multiple sclerosis (MS). In the study, a strong efficacy signal with early onset of action was detected at all doses tested and the product was well tolerated, suggesting that MOR103’s activity compares favourably to that of RA treatments. More data from the study could be reported at the ACR meeting in November. We have raised our valuation from €659m to €697m.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »